by adminAdrianRamirez | May 17, 2016 | Axim Biotechnologies, Company News, Press Releases
MJNA’s Cannabis-Based Drug Development R&D Plans Expand With AXIM Biotech’s Clinical Trials On Patent-Pending AX-1602 Including Cannabigerol (CBG) SAN DIEGO, CA – May 17, 2016 — Medical Marijuana, Inc. (OTC: MJNA) is pleased to announce that its hemp biotech...
by adminAdrianRamirez | May 7, 2016 | Axim Biotechnologies, Cannabis Beauty Defined, Industry Updates, Kannactiv, Media Coverage
This year’s unofficial cannabis holiday brought in nearly $38 million in marijuana sales in the United States, as well as a series of press articles highlighting Medical Marijuana Inc.’s leading position in the country’s booming industry. Retail marijuana...
by adminAdrianRamirez | Apr 22, 2016 | Axim Biotechnologies, Cannabis Beauty Defined, Company News, Kannactiv, Kannaway, Media Coverage
A series of articles aimed at exploring the cannabis industry reveal the range of applications for cannabis and highlight Medical Marijuana Inc.’s influential position in this billion dollar market. It is not surprising that the internet would abound with articles...
by adminAdrianRamirez | Apr 20, 2016 | Axim Biotechnologies, Company News, Kannalife Sciences, Press Releases
MJNA’s Investments Support Development of New Cannabis-Based Medications and Delivery Methods; Developments Further the Reintroduction of Cannabis Medications Globally SAN DIEGO, CA — April 20, 2016 — Medical Marijuana, Inc. (OTC: MJNA) is pleased to announce...
by adminAdrianRamirez | Feb 26, 2016 | Axim Biotechnologies, Company News, Press Releases
AXIM® Biotech Discusses Patented Cannabinoid-Release Chewing Gum – MedChew RX™; Future Patent-Pending Products Including: Oral Care, Skin Care, Suppository, and Ocular Treatments SAN DIEGO, Feb. 25, 2016 (GLOBE NEWSWIRE) — Medical Marijuana, Inc. (OTC Pink:MJNA) is...
by adminAdrianRamirez | Jan 6, 2016 | Axim Biotechnologies, Company News, Media Coverage
Big news today for Medical Marijuana Inc. portfolio company AXIM Biotechnologies, literally. They were featured in an article on Reuters by Natalie Grover, who reported that the cannabis biotechnology company “has a trump card in its quest to develop a...